Asia Pacific Non-Small Cell Lung Cancer Market is expected to grow at a CAGR of 6.7% during the assessment period 2023-2033. Europe is expected to grow at a CAGR of 7% during the assessment period 2023-2033. The chemotherapy segment is expected to hold the largest market share for non-small cell lung cancer.

NEWARK, Del, Dec. 29, 2022 (GLOBE NEWSWIRE) -- A recently published study by FMI expects the global Non-small cell lung cancer market to augment at a 7.2% CAGR from 2023 to 2033. By the end of the said assessment period, a valuation of US$ 20 Billion is expected for the market. From 2018 to 2022, the industry experienced noteworthy growth, registering a value CAGR of 6.7% and closing at US$ 10 Billion. The expansion of the non-small cell lung cancer market may be attributed to an increase in cancer cases as well as increased patient knowledge about their health.

Non-small cell lung cancer, one of the most common kinds of lung cancer, reduces the lungs' ability to provide oxygen to the blood. Non-small cell lung cancer accounts for 80-85% of all lung cancer cases worldwide. The causes are passive smoking, active smoking, consuming polluted water, and being exposed to air pollution. It can, however, be treated with a variety of medicines such as immunotherapy, targeted therapy, and others.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16143

The two primary causes of non-small cell lung cancer are excessive tobacco intake and active participation in passive smoking. Long-term air pollution exposure promotes the development of non-small cell lung cancer. However, the existence of large firms, as well as the entry of new essential players, will result in excessive market rivalry. This will decrease the rate of expansion of the lung cancer treatments market.

The high expense of therapy or treatment will limit the scope of expansion even further. Because of the prevalence of advanced healthcare infrastructure, greater research and development capabilities by pharmaceutical firms, and quick adoption of new and better healthcare technology, North America leads the non-small cell lung cancer market. Asia-Pacific, on the other hand, is expected to have the greatest growth rate throughout the projection period due to increased healthcare infrastructure spending, increasing prevalence of non-small cell lung cancer, and a growing senior population sensitive to cancer.

Key Takeaways from the Market Study

• FMI projects the global non-small cell lung cancer market to expand at a 7.2% value CAGR by 2033
• The global non-small cell lung cancer market is estimated at a market value of US$ 10 Billion
• The global non-small cell lung cancer market is expected to garner a market value of US$ 20 Billion
• North America is forecast to be the most lucrative for non-small cell lung cancer market growth.
• As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 6.7% during the assessment period 2023-2033.
• Europe is expected to grow at a CAGR of 7% during the assessment period 2023-2033.
• The chemotherapy segment is expected to hold the largest market share for non-small cell lung cancer in the forecast period 2023-2033.
  

“Rising investment in research & development efforts by the key players will fuel market expansion even more,” says an analyst at FMI

Get an Exclusive Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16143

Market Competition

Key players in the non-small cell lung cancer market are Novartis Pharmaceuticals, Merck KGaA, Eli Lilly and Company, Hoffmann-La Roche, Xcovery, BeyondSpring Pharmaceuticals, OSE Immunotherapeutics, Sanofi, Takeda, and AbbVie.

Recent Developments:

• In December 2022, Pluvicto®, a targeted radioligand treatment, has been authorised by the European Commission (EC), according to Novartis. Pluvicto® is licensed for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer in conjunction with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition (mCRPC). AR pathway inhibitor and taxane-based chemotherapy were used to treat these individuals.
  

More Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the global non-small cell lung cancer mrket, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023-2033.

The study reveals essential insights on the basis of Cancer Type Squamous Cell Carcinoma, Adenocarcinoma and Large-cell Carcinoma, by Treatment (Chemotherapy, Targeted Therapy and Immunotherapy), across five major regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).

Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-16143

Key Segments Profiled in the Non-Small Cell Lung Cancer Industry Survey

Non-Small Cell Lung Cancer Market by Cancer Type:

• Squamous Cell Carcinoma
• Adenocarcinoma
• Large-cell Carcinoma
  

Non-Small Cell Lung Cancer Market by Treatment:

• Chemotherapy
• Targeted Therapy
• Immunotherapy
  

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

View Full Report @ https://www.futuremarketinsights.com/reports/non-small-cell-lung-cancer-market

About the Healthcare at Future Market Insights

The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.

Have a Look at Related Research Reports of Healthcare Domain:

Orthopedic Braces and Support Market Size: The global orthopedic braces and support market is valued at US$ 4.09 Bn in 2022, which amounts to 38.6% share of the global fracture fixation products market.

Manual Resuscitator Market Trends: The global manual resuscitator market is expected to register a CAGR of 5.7% over the forecast period (2022 - 2030). Revenue from the sales of manual resuscitators is predicted to be valued at US$ 543.3 Mn in 2022 and increase to US$ 845.3 Mn by the end of 2030.

Compression Therapy Market Growth: The global compression therapy marketis set to record a market value of US$ 3.01 Bn in 2022 and reachUS$ 4.59 Bn by 2030, expanding at a CAGR of 5.4%, which indicates steady positive market growth for the forecast period (2022-2030).

Patient Identification Wristbands Market Outlook: Global patient identification wristbands market is set to experience a significant growth of 7.9% CAGR from 2022 to 2030, with an estimated market value of around US$ 460.3 Mn as of 2022.

Medical Nitroglycerin Sprays Market Forecast: Expanding at a CAGR of 4.2%, the global medical nitroglycerin sprays market is projected to increase from a valuation of US$ 106.3 Mn in 2022 to US$ 147.3 Mn by the end of 2030.

About Us :

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
LinkedIn| Twitter| Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com